Advertisement
"We are delighted to welcome Charlie to the Xenon team," commented SimonPimstone, Xenon's President and CEO. "Charlie brings a unique combination ofdrug discovery experience and leadership including in areas that are highlyrelevant to Xenon such as pain. With a drug candidate for pain currently inclinical trials, and a backup compound expected to follow, we are certain thatCharlie's background will be of great benefit to Xenon. In addition to hisexperience in the pain area, Charlie brings broad and diverse expertise whichwill be applicable to our multiple discovery and pre-clinical programs."
Advertisement
Dr. Cohen has spent the past approximately 25 years in thepharmaceutical/biotechnology industry with positions at Bayer Pharmaceuticals,Merck & Co and Vertex Pharmaceuticals. He held senior scientific positions andhas published widely in the area of pain and more broadly in cellularneuroscience and neurology. Dr. Cohen received his PhD in Biophysics andTheoretical Biology from the University of Chicago.
About Xenon Pharmaceuticals Inc.
Xenon is a privately owned, clinical genetics-based drug discovery anddevelopment company engaged in developing small molecule therapies focusing inthe areas of Pain, Diabetes/Obesity, Anemia and Iron Overload. Xenon haspartnerships with Novartis Pharma AG, Roche and Takeda Pharmaceutical CompanyLtd. For more information, visit the Company's website athttp://www.xenon-pharma.com.
This release contains forward-looking statements that are not based onhistorical fact. These forward-looking statements involve risks, uncertaintiesand other factors that may cause the actual results, events or developments tobe materially different from those expressed or implied by suchforward-looking statements. Readers are cautioned not to place undue relianceon such forward-looking statements.
SOURCE Xenon Pharmaceuticals Inc.
